Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn MoreBreast cancer basic research aims to understand the biological mechanisms behind breast cancer development, progression, and metastasis. Alfa Cytology offers a comprehensive suite of basic research services tailored for breast cancer studies.
Breast cancer (BC) is now the most common cancer in the world, and the disease is the leading cause of cancer death among women globally. BC is a heterogeneous disease with considerable genetic and clinical heterogeneity. BC is commonly classified based on aggressiveness, morphology, expression of immunohistochemical markers and, more recently, genomically, features that are associated with different treatment responses and prognoses. Currently, the origin of cancer stem cells, heterogeneity of cancer cells, cancer metastasis mechanisms and drug resistance are the most pressing issues that need to be addressed.
Fig.1 Association between differentiation states of the mammary gland hierarchy and intrinsic breast cancer subtypes. (Yeo SK, et al., 2017)
Alfa Cytology's basic research on BC can help researchers better understand the mechanism, pathogenesis, diagnosis and treatment of BC, and reveal the origin of cancer cells, somatic mutations, epigenetic changes and tumor microenvironment.
Breast cancer cell analysis services
Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC basic research services and help in the treatment and diagnosis of BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.
Reference